ULCaN Seminar Series
Time and Date
Friday, 19th March 2021, 1pm
(via MS Teams)
Microsoft Teams meeting
Join on your computer or mobile app
Speaker: Dr.James Brown, University of Limerick
"Restraining KATs: new therapeutics and breast cancer biomarkers".
The focus of my talk, and my Oncobiology and Molecular Therapeutics Group is exploring the role of lysine acetylation in regulating genome stability, and how this can be controlled by our new targeted inhibitors as the potential next generation of therapeutics. Our fundamental research explores new roles for the lysine acetyltransferase (KAT) Tip60 dependent signalling (focusing on the DNA double strand break response). Our translational projects focus on pre-clinical validation of the in vivo mechanisms of action of our lysine acetyltransferase inhibitor (KATi) TH1834.
The secondary focus in my group is the discovery and validation of breast cancer biomarkers (proteins and miRNA), both circulating in the blood and in tumour biopsies. Our current collaborative projects in this area are utilising AI-based analysis, combined with digital pathology. Our biomarker research aims to validate markers for improved disease and patient stratification, with a focus on improving treatment choice and response prediction.
Dr Brown received his B.App.Sc.(Hons) through the Queensland University of Technology (Brisbane, Australia). He completed his PhD at the Queensland Institute of Medical Research (Brisbane, Australia) under Professor Martin Lavin, exploring the cellular response to genotoxic stress. He moved to NUI Galway undertaking further postdoctoral training within the Centre for Chromosome Biology before setting up his own research group in the Lambe Institute for Translational Research. He took up his current post as principal investigator and lecturer at the University of Limerick in 2019.